Contents

Feature Boxes ........................................... xv
Preface to the Second Edition ................................ xvi
Preface to the First Edition ................................ xix
Acknowledgments ........................................ xxi
About the Companion Website ................................ xxiii

1 Inorganic Chemistry Basics ................................ 1
   1.1 Introduction ......................................... 1
   1.2 Crystal Field Theory ................................ 1
      1.2.1 Octahedral Crystal Field ......................... 2
      1.2.2 Other Crystal Fields ......................... 6
      1.2.3 Factors Affecting the Crystal Field Splitting Parameter, Δ ......... 8
         1.2.3.1 Spectrochemical Series ................. 8
         1.2.3.2 Principal Quantum Number, n .......... 9
         1.2.3.3 Metal Ion Oxidation State .......... 9
      1.2.4 High- and Low-Spin Complexes ............ 10
   1.3 Molecular Orbital Theory ............................ 12
      1.3.1 MO Diagram of Molecular Hydrogen ........... 13
      1.3.2 MO Diagram for [Co(NH₃)₆]³⁺ ............... 15
   1.4 Absorption Spectra of Metal Complexes ............. 22
      1.4.1 Band Intensity/Selection Rules ........... 25
      1.4.2 Absorption Spectra of Multi-Electron Systems ....... 27
   1.5 Magnetic Properties of Metal Complexes ............. 33
   1.6 Structure and Reactivity of Metal Complexes ....... 35
      1.6.1 Forward and Reverse Rates and Equilibrium .... 35
      1.6.2 Water Exchange Rates for Metal Ions ........ 36
      1.6.3 Transition State Theory, the Kinetic Rate Constant and Equilibrium 38
      1.6.4 Trans Effect and Substitution Reactions .... 40
      1.6.5 Stability of Metal Complexes ................. 44
      1.6.6 Chelate Effect ................................... 46
      1.6.7 Macrocyclic Effect .............................. 50
      1.6.8 Hard–Soft Acids–Bases ...................... 52
   1.7 Summary ............................................. 53
Discussion Questions ........................................ 55
Problems .................................................... 55
References ............................................... 57
Further Reading .......................................... 57
2 Metallo-Drugs and Their Action .......................................................... 59
  2.1 Introduction ................................................................................. 59
  2.2 Proteins as Targets for Metallo-Drugs ................................. 59
    2.2.1 Protein Structure .............................................................. 60
    2.2.2 Metal-Binding Sites on Proteins ..................................... 62
  2.3 DNA as a Target for Metallo-Drugs ........................................ 71
    2.3.1 Structure of DNA and RNA ............................................. 71
    2.3.2 Metal-Binding Sites on DNA .......................................... 74
  2.4 Reaction of Metal Complexes in the Biological Milieu ........... 76
    2.4.1 Reactions with Chloride .................................................. 76
    2.4.2 Reactions with Phosphate ............................................... 77
    2.4.3 Reactions with Carbonate .............................................. 77
  2.5 Evaluating the Pharmacological Effects of Agents .............. 79
    2.5.1 Measuring the Cytotoxicity of a Drug .............................. 79
    2.5.2 Measuring Drug Uptake .................................................. 81
    2.5.3 Animal Studies .............................................................. 81
  2.6 From Discovery to the Clinic .................................................. 82
    2.6.1 Preclinical Phase of the Drug-Approval Process .......... 82
    2.6.2 Investigational New Drug (IND) Application ................. 83
    2.6.3 Phase I Clinical Trials ..................................................... 83
    2.6.4 Phase II Clinical Trials ................................................... 83
    2.6.5 Phase III Clinical Trials ................................................ 84
    2.6.6 New Drug Application .................................................... 84
    2.6.7 Post-Marketing .............................................................. 84
    2.6.8 Cost of Research and Development .............................. 84
  2.7 Summary .................................................................................. 85
  Discussion Questions ....................................................................... 86
  Problems ...................................................................................... 87
  References ................................................................................... 88
  Further Reading .......................................................................... 89

3 Platinum Drugs for Treating Cancer ................................................. 91
  3.1 Introduction ............................................................................. 91
  3.2 Cisplatin ................................................................................... 91
    3.2.1 Physical and Chemical Properties of Cisplatin ............... 94
    3.2.2 Formulation, Administration, Pharmacokinetics and Adverse Reactions of Cisplatin 96
    3.2.3 Reaction of Cisplatin in Blood .......................................... 97
    3.2.4 Uptake (Influx) of Cisplatin by Cells .............................. 97
    3.2.5 Removal (Efflux) of Cisplatin from Cells: Resistance ...... 99
    3.2.6 DNA as a Target for Cisplatin ......................................... 100
    3.2.7 Non-DNA Targets for Cisplatin ....................................... 109
      3.2.7.1 Membrane Proteins .................................................. 110
      3.2.7.2 Zinc Finger Proteins ................................................. 110
      3.2.7.3 Tubulin .................................................................. 111
      3.2.7.4 Thioredoxin Reductase .......................................... 112
      3.2.7.5 Stress Response Proteins ....................................... 112
      3.2.7.6 RNA .................................................................. 114
Contents

3.3 Carboplatin .................................................. 115
  3.3.1 Synthesis and Properties of Carboplatin ................. 115
  3.3.2 Formulation, Administration, Pharmacokinetics and Adverse Reactions of Carboplatin .......................... 118
  3.3.3 Carboplatin Activation: Breaking the Ring ................ 118
  3.3.4 Reaction of Carboplatin with Blood Proteins .............. 121
  3.3.5 Cytotoxicity and Uptake of Carboplatin .................. 121
  3.3.6 Interaction of Carboplatin with Cellular Targets ........... 123

3.4 Oxaliplatin .................................................. 126
  3.4.1 Synthesis and Properties of Oxaliplatin .................. 126
  3.4.2 Formulation, Administration, Pharmacokinetics and Adverse Reactions of Oxaliplatin .......................... 128
  3.4.3 Reaction of Oxaliplatin in Blood ........................ 128
  3.4.4 Uptake of Oxaliplatin by Cells .......................... 130
  3.4.5 Interaction of Oxaliplatin with Cellular Targets ........... 130

3.5 Regionally Used Platinum Drugs ................................ 133
  3.5.1 Nedaplatin ............................................. 133
  3.5.2 Lobaplatin ............................................. 134
  3.5.3 Heptaplatin ............................................. 135

3.6 Platinum Agents in Preclinical Development ..................... 135
  3.6.1 Sterically Hindered Agents .............................. 135
  3.6.2 Compounds with the Trans Geometry ...................... 136
  3.6.3 Biologically Active ‘Cargo’ Molecules .................... 137
  3.6.4 Monofunctional Platinum Complexes ...................... 137
  3.6.5 Multinuclear Platinum Compounds ......................... 137
  3.6.6 Platinum(IV) Prodrugs .................................. 138
  3.6.7 Platinum Compounds that do not Attack DNA ............. 140
  3.6.8 Lipoplatin .............................................. 140

3.7 Summary ..................................................... 141
Discuss Questions ............................................. 143
Problems ....................................................... 144
References ...................................................... 146

4 Anticancer Agents Beyond Cisplatin ................................ 157
  4.1 Introduction ............................................... 157
  4.2 Ruthenium Anticancer Agents ................................. 157
    4.2.1 Chemistry of Ruthenium in the Biological Milieu ........ 157
    4.2.2 Structure, Synthesis and Properties of Ruthenium Antitumor Agents .................. 158
    4.2.3 Synthesis and Biological Properties of NAMI-A ............ 159
    4.2.4 Control of Tumor Growth by NAMI-A ....................... 163
    4.2.5 Clinical Trials with NAMI-A ............................. 163
    4.2.6 Interaction of NAMI-A with Potential Biological Targets ...... 163
    4.2.7 Synthesis and Reactivity of KP1019 ....................... 165
    4.2.8 Anticancer and Biological Activity of KP1019 ............ 165
    4.2.9 Interaction of KP1019 with Biological Molecules .......... 166
    4.2.10 Synthesis and Properties of Ruthenium Arene (Half-Sandwich) Compounds ........ 168
    4.2.11 Biological Activity of the Arene Complexes ................ 169
# Contents

4.3 Gold Anticancer Agents ................................................................. 173  
4.3.1 Structures, Synthesis and Properties of Gold Anticancer Agents ........ 173  
4.3.2 Cellular Targets of the Gold Anticancer Agents ............................. 176  
4.4 Titanium Compounds for Treating Cancer .......................................... 181  
4.4.1 Structure, Synthesis and Properties of Titanocene Dichloride .......... 182  
4.4.2 Interaction of Titanocene Dichloride with Potential Biological Targets ... 183  
4.4.3 Structure, Synthesis, and Properties of Budotitane ......................... 183  
4.4.4 Antitumor Activity and Clinical Trials with Budotitane ................. 184  
4.4.5 Biological Interactions of Budotitane ........................................ 184  
4.4.6 Titanium Anticancer Drugs in Development .................................. 184  
4.5 Gallium for Treating Cancer .......................................................... 187  
4.5.1 Chemistry of Gallium in Biological Media ................................... 187  
4.5.2 Structures, Synthesis and Properties of Gallium Anticancer Agents ..... 188  
4.5.3 Uptake, Cytotoxicity and Reactivity of Gallium Agents in the Biological System 189  
4.5.4 Gallium Anticancer Agents in Development .................................. 193  
4.6 Other Anticancer Active Metal Complexes ........................................ 194  
4.6.1 Palladium .................................................................................. 194  
4.6.2 Osmium .................................................................................... 196  
4.6.3 Rhodium and Iridium ................................................................. 199  
4.7 Summary ....................................................................................... 201  
Discussion Questions .............................................................................. 203  
Problems ................................................................................................. 204  
References .............................................................................................. 206  
Further Reading ....................................................................................... 216  

5 Responsive Metal Complexes .............................................................. 217  
5.1 Introduction ..................................................................................... 217  
5.2 Prodrug Activation by Redox ............................................................ 217  
5.2.1 Platinum ..................................................................................... 217  
5.2.2 Cobalt ......................................................................................... 220  
5.2.3 Copper ......................................................................................... 222  
5.2.4 Iron ............................................................................................. 222  
5.3 Prodrug Activation by pH ................................................................. 225  
5.4 Prodrug Activation by Enzymes ......................................................... 227  
5.5 Prodrug Activation by Light ............................................................... 229  
5.5.1 Photo-Release of a Cytotoxic Metal Complex ................................. 229  
5.5.2 Photo-Release of Bound Drug Molecules ...................................... 230  
5.5.3 Photo-Release of Cell-Signaling Molecules .................................... 231  
5.6 Photodynamic Therapy ...................................................................... 233  
5.6.1 Porphyrins .................................................................................. 233  
5.6.2 Phthalocyanines ........................................................................... 236  
5.6.3 Texaphyrins ................................................................................ 237  
5.6.4 Bacterioopheophorbides ............................................................... 237  
5.7 Summary ......................................................................................... 237  
Discussion Questions .............................................................................. 238  
Problems ................................................................................................. 239  
References .............................................................................................. 240  
Further Reading ....................................................................................... 244
Contents

6 Metal Complexes for Treating Arthritis and Diabetes ........................................ 245
   6.1 Introduction ........................................................................................................ 245
   6.2 Chemistry of Gold in Biological Media ............................................................. 245
   6.3 Gold Compounds for Treating Arthritis ............................................................ 247
      6.3.1 Structures, Synthesis and Properties of Gold Anti-Arthritic Drugs ................ 247
      6.3.2 Formulation, Administration and Pharmacokinetics of Gold Anti-Arthritic Drugs 250
      6.3.3 Reactions of Gold Drugs in Biological Media .............................................. 250
      6.3.4 Interaction of Gold Drugs with Cellular Targets ........................................ 254
         6.3.4.1 Glutathione Reductase ........................................................................ 258
         6.3.4.2 Zinc Finger Proteins ........................................................................... 258
         6.3.4.3 Protein Tyrosine Phosphatases ........................................................... 262
   6.4 Vanadium Compounds for Treating Diabetes ................................................... 263
      6.4.1 Diabetes Mellitus ......................................................................................... 264
      6.4.2 Bis(ethylmaltolato)oxovanadium(IV) and Bis(maltolate)oxovanadium(IV) .......... 265
      6.4.3 Other Vanadium Complexes with Insulin-Mimetic Properties ...................... 273
   6.5 Summary ............................................................................................................. 276
   Discussion Questions ................................................................................................. 277
   Problems ................................................................................................................... 278
   References ................................................................................................................. 279
   Further Reading .......................................................................................................... 283

7 Metal Complexes for Killing Parasites, Bacteria and Viruses .................................. 285
   7.1 Introduction ........................................................................................................... 285
   7.2 Malaria .................................................................................................................. 286
      7.2.1 Antimalarial Drugs ....................................................................................... 291
      7.2.2 Metallo-Antimalarial Agents ....................................................................... 291
   7.3 Leishmaniasis ....................................................................................................... 293
      7.3.1 Antileishmanial Drugs .................................................................................. 294
      7.3.2 Antileishmanial Drugs in Development ...................................................... 296
   7.4 American Trypanosomiasis (Chagas Disease) ...................................................... 298
      7.4.1 Trypanocidal Drugs ...................................................................................... 298
      7.4.2 Metallo-Trypanocidal Drugs in Development ........................................... 299
   7.5 Human African Trypanosomiasis ........................................................................ 301
   7.6 Tuberculosis ......................................................................................................... 301
      7.6.1 The Antituberculosis Drug, Isoniazid .......................................................... 303
      7.6.2 Metallo-Antituberculosis Drugs in Development ......................................... 303
   7.7 Peptic Ulcer Disease ............................................................................................ 306
      7.7.1 Bismuth Anti-Ulcer Drugs ........................................................................... 307
      7.7.2 Metallo-Anti-Ulcer Drugs in Development ................................................. 309
      7.7.3 Metallo-Drugs for Treating Minor Gastrointestinal Disorders ...................... 310
   7.8 Syphilis ................................................................................................................ 311
   7.9 Bacterial Infections ............................................................................................. 312
   7.10 Acquired Immunodeficiency Syndrome (AIDS) .................................................. 314
   7.11 Summary ............................................................................................................. 318
   Discussion Questions ................................................................................................. 320
   Problems ................................................................................................................... 320
   References ................................................................................................................. 321
Contents

8 Metal Ion Imbalance in the Body ................................................................. 329
  8.1 Introduction ......................................................................................... 329
  8.2 Alzheimer’s Disease ........................................................................ 329
    8.2.1 The Amyloid Cascade Hypothesis .................................................. 329
    8.2.2 The Metal Ion Hypothesis .............................................................. 330
    8.2.3 The Oxidative Stress Hypothesis ..................................................... 332
    8.2.4 Metal-Chelating Agents for Treating Alzheimer’s Disease .......... 334
      8.2.4.1 Clioquinol .............................................................................. 335
      8.2.4.2 Deferiprone ............................................................................ 336
  8.3 Lithium and the Brain ......................................................................... 337
  8.4 Wilson’s Disease: Copper Overload ..................................................... 338
  8.5 Menkes Disease: Copper Deficiency ..................................................... 340
  8.6 Beta-Thalassemia: Iron Overload ......................................................... 342
    8.6.1 Desferrioxamine B .......................................................................... 342
    8.6.2 Deferiprone ................................................................................... 343
    8.6.3 Deferasirox ................................................................................... 343
  8.7 Iron-Deficiency Anemia ..................................................................... 344
  8.8 Calcium Imbalance ............................................................................ 344
  8.9 Chelation Therapy ............................................................................. 346
  8.10 Summary ............................................................................................ 348
  Discussion Questions ................................................................................ 349
  Problems .................................................................................................. 350
  References ................................................................................................ 351
  Further Reading ....................................................................................... 356

9 Metal Complexes for Detecting Disease ......................................................... 357
  9.1 Introduction ......................................................................................... 357
  9.2 Technetium in Diagnostic Nuclear Medicine ....................................... 358
    9.2.1 Clinically Used 99mTc Imaging Agents ............................................ 361
    9.2.2 Technetium Drugs for Selective Targeting ..................................... 366
    9.2.3 Innovations in Synthesis: The [Tc(CO)3]+ Core .............................. 368
  9.3 Metal Compounds as Contrast Agents for MRI .................................... 371
    9.3.1 Clinically Used MRI Contrast Agents ............................................ 376
      9.3.1.1 Magnevist ............................................................................... 377
      9.3.1.2 Dotarem ................................................................................. 378
      9.3.1.3 Ablavar ................................................................................. 378
      9.3.1.4 Teslascan ............................................................................... 380
    9.3.2 Contrast Agents in Development .................................................... 381
  9.4 Radiotherapy ....................................................................................... 382
  9.5 Summary ............................................................................................. 386
  Discussion Questions ................................................................................ 387
  Problems .................................................................................................. 387
  References ................................................................................................ 389
  Further Reading ....................................................................................... 393

10 Nanomedicine .............................................................................................. 395
  10.1 Introduction ....................................................................................... 395
  10.2 Circulation, Uptake, and Elimination of Nanoparticles ...................... 396
Contents

10.2.1 The Mononuclear Phagocyte System ................................. 396
10.2.2 Enhanced Permeation and Retention (EPR) Effect .................. 399
10.2.3 Cell-Targeting Groups ........................................... 400
10.2.4 Uptake of NPs by Cells .......................................... 401
  10.2.4.1 Endocytosis ................................................. 401
  10.2.4.2 Silver Nanoparticles ......................................... 401
  10.2.4.3 Gold Nanoparticles .......................................... 401
  10.2.4.4 Carbon Nanotubes .......................................... 403
  10.2.4.5 Superparamagnetic Iron Oxide Nanoparticles ............... 404
  10.2.4.6 Mesoporous Nanoparticles .................................. 404
  10.2.4.7 Quantum Dots .............................................. 404
  10.2.4.8 Metal Organic Frameworks ................................... 406
10.2.5 Biodistribution of Nanoparticles in the Body ..................... 406

10.3 Nanoscience for Treating Cancer ...................................... 407
  10.3.1 Gold Nanoparticles ............................................ 407
  10.3.2 Mesoporous Silica Nanoparticles (MSNPs) ...................... 414
  10.3.3 Nano Metal–Organic Frameworks (NMOFs) ....................... 417

10.4 Nanoparticles for Detecting Disease .................................. 419
  10.4.1 Magnetic Resonance Imaging (MRI) ............................ 419
  10.4.2 Fluorescence Spectroscopy (FL) ................................ 421

10.5 Theranostic Nanoparticles ............................................ 426
10.6 Cytotoxicity of Nanoparticles ........................................ 428
10.7 Summary ............................................................. 429
Discussion Questions ....................................................... 431
Problems ................................................................. 432
References ................................................................. 433

Index .............................................................................. 441